12:00 AM
 | 
Sep 07, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/4 cls
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) JMP Securities Charles Duncan Price target Market outperform -66% $2.03
Piper Jaffray Edward Tenthoff Price target Underweight
Duncan lowered his target to $5 from $7 after Acadia's lead candidate pimavanserin missed the primary endpoint of antipsychotic efficacy as measured by the Scale for the Assessment of Positive Symptoms (SAPS) in a Phase III trial in Parkinson's disease psychosis (PDP). He noted the improvement in SAPS scores for placebo was greater than expected, and said "it makes more sense to interpret these results as a failure of the control group to not respond to placebo, rather than a failure of the drug arms to respond to...

Read the full 820 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >